Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Prednisolone
Drug ID BADD_D01831
Description Prednisolone is a glucocorticoid similar to [cortisol] used for its anti-inflammatory, immunosuppressive, anti-neoplastic, and vasoconstrictive effects.[A187463] Prednisolone was granted FDA approval on 21 June 1955.[L9431]
Indications and Usage Prednisolone is indicated to treat endocrine, rheumatic, and hematologic disorders; collagen, dermatologic, ophthalmic, respiratory, and gastrointestinal diseases; allergic and edematous states; and other conditions like tuberculous meningitis.[L9542]
Marketing Status approved; vet_approved
ATC Code A01AC04; A07EA01; C05AA04; D07AA03; D07XA02; H02AB06; R01AD02; S01BA04; S01CB02; S02BA03; S03BA02
DrugBank ID DB00860
KEGG ID D00472
MeSH ID D011239
PubChem ID 5755
TTD Drug ID D0D1SG
NDC Product Code 38779-0150; 64958-0097; 82298-104; 67296-1656; 50383-042; 59651-491; 63187-466; 0527-5406; 65089-0038; 50090-0655; 57582-004; 62135-437; 73534-505; 49452-5980; 82298-105; 82298-106; 60592-911; 60722-3001; 51927-0234; 22552-0052
UNII 9PHQ9Y1OLM
Synonyms Prednisolone | Predate | Predonine | Di-Adreson-F | Di Adreson F | DiAdresonF
Chemical Information
Molecular Formula C21H28O5
CAS Registry Number 50-24-8
SMILES CC12CC(C3C(C1CCC2(C(=O)CO)O)CCC4=CC(=O)C=CC34C)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Neurosarcoidosis10.02.06.005; 17.06.01.0050.000035%-
No reaction on previous exposure to drug08.06.01.0420.000035%-
Omental infarction07.15.02.017; 24.04.08.0230.000035%-
Organic brain syndrome19.07.03.0110.000035%-
Pancreatic failure07.18.02.0110.000052%-
Penetrating aortic ulcer24.02.03.0070.000035%-
Penetrating atherosclerotic ulcer24.03.04.0160.000035%-
Periorbital swelling06.08.03.032; 10.01.05.025; 23.04.01.0250.000035%-
Pharyngeal swelling22.04.05.0280.000052%-
Pleural adhesion22.05.03.0050.000035%-
Pleuroperitoneal communication07.07.01.017; 12.02.18.003; 22.05.02.0120.000052%-
Polychondritis10.04.04.031; 15.07.03.0100.000052%-
Polyglandular autoimmune syndrome type III05.09.02.003; 10.04.08.0030.000070%-
Primary adrenal insufficiency05.01.02.012; 14.11.01.0560.000052%-
Rectosigmoid cancer07.21.01.023; 16.13.01.0240.000035%-
Retinal drusen06.09.03.0340.000315%-
Sebaceous glands overactivity23.02.07.0080.000035%-
Sensory processing disorder17.02.03.025; 19.22.02.0050.000035%-
Serous retinal detachment06.09.03.0370.000087%-
Sinus pain22.12.03.0230.000035%
Skin weeping23.03.03.1010.000035%-
Squamous cell carcinoma of the vagina16.12.09.001; 21.08.03.0080.000052%-
Steroid dependence08.06.01.0470.000077%-
Steroid diabetes05.06.01.019; 14.06.01.0190.000699%-
Still's disease08.05.02.017; 10.02.07.002; 15.01.03.0070.000087%-
Swelling of eyelid06.04.04.018; 10.01.05.026; 23.04.01.0260.000035%-
Therapeutic product effect incomplete08.06.01.0520.000584%-
Therapeutic response changed08.06.01.0590.000077%-
Therapy non-responder08.06.01.0630.000619%-
Therapy partial responder08.06.01.0640.000087%-
The 35th Page    First    Pre   35 36    Next   Last    Total 36 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene